Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
Pear Therapeutics and PreferredOne Announce Broad Based Patient Access and Reimbursement for reSET® and reSET-O® for People with Substance Use Disorder and Opioid Use Disorder
Read Article
News
2020
2019
Archive
August 26, 2020
Vor Biopharma Appoints John King as Chief Commercial Officer
August 25, 2020
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
August 20, 2020
Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutics reSET® and reSET-O® and People with Substance and Opioid Use Disorders
August 18, 2020
Purigen Transforms Oncology Sample Preparation with Novel RNA Purification Kit for Challenging Clinical FFPE Specimens
August 14, 2020
Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from Caribou Biosciences and License to CRISPR-Cas9 Foundational Patent Portfolio
August 5, 2020
Akouos Announces Expansion of Executive Team and Board of Directors
August 5, 2020
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment
July 28, 2020
Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
July 27, 2020
scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission
July 22, 2020
Nouscom Highlights Cutting-Edge Science That Led to the Design of NOUS-209, A Potential Off-The-Shelf Neoantigen Cancer Vaccine for Tumors with Microsatellite Instability
« Previous Page
1
2
3
4
…
67
Next Page »
